• FDA approves Samsung/Merck & Co’s Herceptin biosimilar pharmaphorum
    January 23, 2019
    The FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck & Co, ahead of the original drug’s US patent expiry in June.
  • Pfizer notches two EU approvals, including Herceptin biosimilar pharmafile
    August 02, 2018
    Pfizer is patting itself on the back after securing two new approvals in Europe within 24 hours: Xeljanz (tofacitinib citrate) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients for whom other therapies have prove
PharmaSources Customer Service